ORCL vs. AZN
ORCL (Oracle Corporation) and AZN (AstraZeneca PLC) are both stocks. ORCL operates in Software - Infrastructure (Technology), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, ORCL returned 20.30%/yr vs 15.85%/yr for AZN. At a 0.21 correlation, their price movements are largely independent.
Performance
ORCL vs. AZN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ORCL achieves a 9.34% return, which is significantly higher than AZN's 0.81% return. Over the past 10 years, ORCL has outperformed AZN with an annualized return of 20.30%, while AZN has yielded a comparatively lower 15.85% annualized return.
ORCL
- 1D
- -0.87%
- 1M
- 8.10%
- YTD
- 9.34%
- 6M
- -3.36%
- 1Y
- 22.94%
- 3Y*
- 25.94%
- 5Y*
- 21.81%
- 10Y*
- 20.30%
AZN
- 1D
- -2.37%
- 1M
- -0.71%
- YTD
- 0.81%
- 6M
- 1.53%
- 1Y
- 28.04%
- 3Y*
- 9.54%
- 5Y*
- 12.08%
- 10Y*
- 15.85%
ORCL vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ORCL Oracle Corporation | 9.34% | 18.13% | 59.99% | 30.94% | -4.65% | 36.89% | 24.25% | 19.34% | -2.97% | 24.94% |
AZN AstraZeneca PLC | 0.81% | 43.30% | -0.62% | 1.44% | 19.14% | 19.66% | 3.12% | 35.68% | 13.86% | 33.10% |
Correlation
The correlation between ORCL and AZN is -0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.02 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.14 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since May 18, 1993 | 0.21 |
The correlation between ORCL and AZN shifts across timeframes, from -0.02 (1 year) to 0.21 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ORCL:
$617.24B
AZN:
$283.40B
ORCL:
$5.56
AZN:
$6.66
ORCL:
38.09
AZN:
27.27
ORCL:
8.54
AZN:
0.04
ORCL:
9.64
AZN:
4.69
ORCL:
15.81
AZN:
5.99
ORCL:
$64.08B
AZN:
$60.44B
ORCL:
$58.10B
AZN:
$49.37B
ORCL:
$17.85B
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ORCL vs. AZN — Risk / Return Rank
ORCL
AZN
ORCL vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Oracle Corporation (ORCL) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ORCL | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.76 | ||
| Sortino ratioReturn per unit of downside risk | -0.72 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.21 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 0.40 | 1.83 | -1.44 |
| Martin ratioReturn relative to average drawdown | 0.66 | 4.90 | -4.24 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ORCL | AZN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.35 | 1.11 | -0.76 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.52 | 0.51 | +0.02 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.58 | 0.64 | -0.06 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.49 | 0.49 | 0.00 |
Drawdowns
ORCL vs. AZN - Drawdown Comparison
The maximum ORCL drawdown since its inception was -84.19%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for ORCL and AZN.
Loading charts...
Drawdown Indicators
| ORCL | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.19% | -48.94% | -35.25% |
Max Drawdown (1Y)Largest decline over 1 year | -58.25% | -15.43% | -42.82% |
Max Drawdown (3Y)Largest decline over 3 years | -58.25% | -27.87% | -30.38% |
Max Drawdown (5Y)Largest decline over 5 years | -58.25% | -27.87% | -30.38% |
Max Drawdown (10Y)Largest decline over 10 years | -58.25% | -27.87% | -30.38% |
Current DrawdownCurrent decline from peak | -34.98% | -12.90% | -22.08% |
Average DrawdownAverage peak-to-trough decline | -29.10% | -11.37% | -17.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.04% | 5.75% | +29.29% |
Volatility
ORCL vs. AZN - Volatility Comparison
Oracle Corporation (ORCL) has a higher volatility of 21.62% compared to AstraZeneca PLC (AZN) at 7.42%. This indicates that ORCL's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ORCL | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.62% | 7.42% | +14.20% |
Volatility (6M)Calculated over the trailing 6-month period | 42.42% | 17.47% | +24.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.38% | 25.55% | +39.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 41.98% | 24.02% | +17.96% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.01% | 24.94% | +10.07% |
Dividends
ORCL vs. AZN - Dividend Comparison
ORCL's dividend yield for the trailing twelve months is around 0.94%, less than AZN's 2.93% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AZN AstraZeneca PLC | 2.93% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
ORCL Oracle Corporation | 0.94% | 0.97% | 0.96% | 1.44% | 1.57% | 1.38% | 1.48% | 1.72% | 1.68% | 1.52% | 1.56% | 1.56% |
Financials
ORCL vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Oracle Corporation and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ORCL and AZN have a correlation of -0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ORCL has higher volatility (21.62%) compared to AZN (7.42%). In terms of maximum drawdown, ORCL dropped -84.19% vs AZN's -48.94%.
AZN currently has the higher Sharpe Ratio (1.11 vs 0.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ORCL and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer